GlassScriptPhysician profile
Vinod Sancheti
NPI 1437176088
$3,189.52
in general payments reported to CMS, 2019-2025
26 companies · $698 in 2025
The $698 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $27.84 · 2021: $271 · 2022: $344 · 2023: $942 · 2024: $604 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,244.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $772.40 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $677.63 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Boston Scientific Corporation | $378.18 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $284.18 | 2022-2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $157.16 | 2022-2025 | |
| Silk Road Medical, INC. | $122.03 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Becton, Dickinson and Company | $120.81 | 2024 | Phasix Mesh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.85 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $69.98 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $68.41 | 2023 | Gemtesa |
| Abbott Laboratories | $60.30 | 2023-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $58.94 | 2023 | Seglentis, Livalo |
| Pfizer INC. | $44.22 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.90 | 2025 | Caplyta |
| Amgen INC. | $34.21 | 2025 | Otezla, Repatha |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $31.38 | 2024 | Wegovy, Rybelsus, Ozempic |
| Ucb, INC. | $28.82 | 2023-2024 | Briviact, Nayzilam |
| Exact Sciences Corporation | $23.93 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $21.18 | 2023 | Dexcom G6 Transmitter |
| Intuity Medical INC | $19.07 | 2022 | |
| Lilly USA, LLC | $16.51 | 2025 | Jardiance |
| Esperion Therapeutics, INC. | $15.06 | 2025 | Nexletol |
| Sunovion Pharmaceuticals INC. | $14.90 | 2022 | |
| Philips North America LLC | $13.94 | 2024 | (Ak6) Vest Therapy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.92 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinod Sancheti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.